GLP1R and thyroid cancer: Therefore, this study adds to the available evidence about GLP1 receptor agonist use and risk of thyroid cancer, and supports the conclusion of a recent European Medicines Agency investigation that the available evidence does not support a causal association between GLP1 receptor agonist use and thyroid cancer.9